"Lovastatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.
| Descriptor ID |
D008148
|
| MeSH Number(s) |
D02.455.426.559.847.638.400 D04.615.638.400
|
| Concept/Terms |
Lovastatin- Lovastatin
- Mevinolin
- Monacolin K
- 6-Methylcompactin
- 6 Methylcompactin
|
Below are MeSH descriptors whose meaning is more general than "Lovastatin".
Below are MeSH descriptors whose meaning is more specific than "Lovastatin".
This graph shows the total number of publications written about "Lovastatin" by people in this website by year, and whether "Lovastatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 1 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lovastatin" by people in Profiles.
-
Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer. J Natl Cancer Inst. 2017 05; 109(5).
-
Impact of statin use on survival in patients undergoing resection for early-stage pancreatic cancer. Am J Gastroenterol. 2015 Aug; 110(8):1233-9.
-
Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study. Drug Saf. 2008; 31(4):325-34.
-
Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf. 2008 Jan; 17(1):27-36.
-
What do medical records tell us about potentially harmful co-prescribing? Jt Comm J Qual Patient Saf. 2007 Jul; 33(7):395-400.
-
Successful conversion of patients with hypercholesterolemia from a brand name to a generic cholesterol-lowering drug. Am J Manag Care. 2005 Sep; 11(9):546-52.